G. Sottilotta, G. Giuffrida
Abstract
Hemophilia A and B, but also other congenital and acquired hemorrhagic pathologies, have known epochal changes in the last few years: the new extended half-life factor VIII and IX concentrates, the imminent gene therapy and the non-replacement haemophilia products are offering medical assistance and a quality of life unimaginable in the past. The challenge for the health professionals who every day deal with coagulopathic patients is the choice of the best product tailored to the characteristics and lifestyle of the patient. The COVID-19 emergency seems to have slowed down the possibility of taking advantage of those innovations.
If this is true for industrialized countries like Italy, which still benefit from a satisfying free national health service, for developing countries in the rest of the world, this has impaired the access to care for patients with bleeding disorders. The objective of this 7th interregional conference is also to mark the restart of the scientific and informative activities that have always characterized the spirit of this initiative since its first edition.
(»Download here full PDF version)
